This page contains a Flash digital edition of a book.
PEER-REVIEW | NEUROSCIENCE |


towards reducing the impact of stress, balancing the


energy metabolism, and maintaining the normal levels of neurotransmitters and adrenal hormones.


Conclusions Stress is inevitable, but the consequences of stress are modifiable if the pathophysiologic basis of effects of stress and fatigue are well understood, and enough education and support is provided to the patient. Fatigue being a subjective feeling is a very hard diagnosis to establish. This leads to a prolonged period of dilemma and delay in treatment. In such scenarios, simply by keeping the point in mind that


References


1. Fukuda K, Straus SE, Hickie I, Sharpe MC, Dobbins JG, Komaroff A. The chronic fatigue syndrome: a comprehensive approach to its definition and study. Ann Intern Med 1994; 121: 953–9


2. Chronic Fatigue Syndrome: Diagnosis. Centers for Disease Control and Prevention. Atlanta, GA: CDC, 2012. www.cdc.gov/ cfs/diagnosis/index.html (accessed 4 January 2013)


3. Avellaneda Fernández A, Pérez Martín A, Izquierdo Martínez M et al. Chronic fatigue syndrome: aetiology, diagnosis and treatment. BMC Psychiatry 2009; 9(Suppl 1): S1


4. Cleare AJ. The neuroendocrinology of chronic fatigue syndrome. Endocr Rev 2003; 24(2): 236–52


5. America’s #1 Health Problem. The American Institute of Stress. New Tork, NY: AIS, 2012. www.stress.org/americas-1- health-problem/ (accessed 4 January 2013)


6. Langelaan S, Bakker AB, Schaufeli WB, van Rhenen W, van Doornen LJ. Do burned-out and work-engaged employees differ in the functioning of the hypothalamic-pituitary-adrenal axis? Scand J Work Environ Health 2006; 32(5): 339–48


7. Stress in America. American Psychological Association, 2008. www.apa.org/news/press/releases/2008/10/ stress-in-america.pdf (accessed 4 January 2013)


8. Allison TG, Williams DE, Miller TD et al. Medical and economic costs of psychologic distress in patients with coronary artery disease. Mayo Clin Proc 1995; 70(8): 734–42


9. Kawachi I, Sparrow D, Spiro A 3rd, Vokonas P, Weiss ST. A prospective study of anger and coronary heart disease. The Normative Aging Study. Circulation 1996; 94(9): 2090–5


10. Kawachi I, Sparrow D, Vokonas PS, Weiss ST. Symptoms of anxiety and risk of coronary heart disease. The Normative Aging Study. Circulation 1994; 90(5): 2225–9


11. Kubzansky LD, Kawachi I, Spiro A 3rd, Weiss ST, Vokonas PS, Sparrow D. Is worrying bad for your heart? A prospective study of worry and coronary heart disease in the Normative Aging Study. Circulation 1997; 95(4): 818–24


12. Opstad K. Circadian rhythm of hormones is extinguished during prolonged physical stress, sleep and energy deficiency in young men. Eur J Endocrinol 1994; 131(1): 56–66


13. Esterling BA, Kiecolt-Glaser JK, Bodnar JC, Glaser R. Chronic stress, social support, and persistent alterations in the natural killer cell response to cytokines in older adults. Health Psychol 1994; 13(4): 291–8


14. Monteleone P, Beinat L, Tanzillo C, Maj M, Kemali D. Effects of phosphatidylserine on the neuroendocrine response to physical stress in humans. Neuroendocrinology 1990; 52(3): 243–8


15. Fahey TD, Pearl MS. The hormonal and perceptive effects of phosphatidylserine administration during two weeks of resistive exercise-induced overtraining. Biol Sport 1998; 15:


62 ❚ 135–44


16. Monteleone P, Maj M, Beinat L, Natale M, Kemali D. Blunting by chronic phosphatidylserine administration of the stress-induced activation of the hypothalamo-pituitary- adrenal axis in healthy men. Eur J Clin Pharmacol 1992; 42(4): 385–8


17. Starks MA, Starks SL, Kingsley M, Purpura M, Jäger R. The effects of phosphatidylserine on endocrine response to moderate intensity exercise. J Int Soc Sports Nutr 2008; 5: 11


18. Ito K, Nagato Y, Aoi N et al. Effects of L-theanine on the release of alpha-brain waves in human volunteers. Nippon Nogeikagaku Kaishi 1998; 72: 153–7


19. Nobre AC, Rao A, Owen GN. L-theanine, a natural constituent in tea, and its effect on mental state. Asia Pac J Clin Nutr 2008; 17(Suppl 1): 167–8


20. Kimura K, Ozeki M, Juneja LR, Ohira H. L-Theanine reduces psychological and physiological stress responses. Biol Psychol 2007; 74(1): 39–45


21. Fomichev VI, Pchelintsev VP. The neurohumoral systems of patients with ischemic heart disease and under emotional-pain stress: the means for their pharmacological regulation. Kardiologiia 1993; 33(10): 15–8


22. Spila B, Szumillo A. Gabapentin (GBP) in panic disorders – case report. Psychiatr Pol 2006; 40(6): 1061–8


23. Streeter CC, Jensen JE, Perlmutter RM et al. Yoga Asana sessions increase brain GABA levels: a pilot study. J Altern Complement Med 2007; 13(4): 419–26


24. Khom S, Baburin I, Timin E et al. Valerenic acid potentiates and inhibits GABA(A) receptors: molecular mechanism and subunit specificity. Neuropharmacology 2007; 53(1): 178–87


25. Geuze E, van Berckel BN, Lammertsma AA et al. Reduced GABAA benzodiazepine receptor binding in veterans with post- traumatic stress disorder. Mol Psychiatry 2008; 13(1): 74–83


26. Van Praag HM, Lemus C. Monoamine precursors in the treatment of psychiatric disorders. In: Wurtman RJ, Wurtman JJ. eds, Nutrition and the Brain. New York, NY: Raven Press, 1986


27. den Boer JA, Westenberg HG. Behavioral, neuroendocrine, and biochemical effects of 5-hydroxytryptophan administration in panic disorder. Psychiatry Res 1990; 31(3): 267–78


28. Chadwick D, Jenner P, Harris R, Reynolds EH, Marsden CD.. Manipulation of brain serotonin in the treatment of myoclonus. Lancet 1975; 2(7932): 434–5


29. Shurtleff D, Thomas JR, Schrot J, Kowalski K, Harford R. Tyrosine reverses a cold-induced working memory deficit in humans. Pharmacol Biochem Behav 1994; 47(4): 935–41


30. Deijen JB, Wientjes CJ, Vullinghs HF, Cloin PA, Langefeld JJ. Tyrosine improves cognitive performance and reduces blood


pressure in cadets after one week of a combat training course. Brain Res Bull 1999; 48(2): 203–9


31. Shurtleff D, Thomas JR, Schrot J, Kowalski K, Harford R. Tyrosine reverses a cold-induced working memory deficit in humans. Pharmacol Biochem Behav 1994; 47(4): 935–41


32. Dollins AB, Krock LP, Storm WF, Wurtman RJ, Lieberman HR. L-tyrosine ameliorates some effects of lower body negative pressure stress. Physiol Behav 1995; 57(2): 223–30


33. Vinogradov VV, Tarasov IuA, Tishin VS, Bogdanovich VI, Spas VV. Thiamine prevention of the corticosteroid reaction after surgery. Probl Endokrinol (Mosk) 1981; 27(3): 11–6


34. Robinson CR, Pegram GV, Hyde PR, Beaton JM, Smythies JR. The effects of nicotinamide upon sleep in humans. Biol Psychiatry 1977; 12(1): 139–43


35. Baschetti R. Similarity of symptoms in chronic fatigue syndrome and Addison’s disease. Eur J Clin Invest 1997; 27(12): 1061–2


36. Baschetti R. Treatment for chronic fatigue syndrome [letter]. Arch Intern Med 1998; 158: 2266


37. Papadopoulos E, Crofford LJ, Engleberg NC et al. Impaired HPA axis activity in chronic fatigue syndrome and fibromyalgia. Biol Psychiatry 1997; 41: 29S


38. Demitrack MA, Crofford LJ. Evidence for and pathophysiologic implications of hypothalamic-pituitary- adrenal axis dysregulation in fibromyalgia and chronic fatigue syndrome. Ann N Y Acad Sci 1998; 840: 684–97


39. Cleare AJ, Bearn J, Allain T et al. Contrasting neuroendocrine responses in depression and chronic fatigue syndrome. J Affect Disord 1995; 34(4): 283–9


40. Cleare AJ, Heap E, Malhi GS, Wessely S, O’Keane V, Miell J. Low-dose hydrocortisone in chronic fatigue syndrome: a randomised crossover trial. Lancet 1999; 353(9151): 455–8


41. McKenzie R, O’Fallon A, Dale J et al. Low-dose hydrocortisone for treatment of chronic fatigue syndrome: a randomized controlled trial. JAMA 1998; 280(12): 1061–6


42. Kuratsune H, Yamaguti K, Sawada M et al. Dehydroepiandrosterone sulfate deficiency in chronic fatigue syndrome. Int J Mol Med 1998; 1(1): 143–6


43. De Becker P, De Meirleir K, Joos E et al. Dehydroepiandrosterone (DHEA) response to i.v. ACTH in patients with chronic fatigue syndrome. Horm Metab Res 1999; 31(1): 18–21


44. Dahlitz M, Alvarez B, Vignau J, English J, Arendt J, Parkes JD. Delayed sleep phase syndrome response to melatonin. Lancet 1991; 337(8750): 1121–4


Stress is inevitable, but the


consequences of stress are modifiable if the


stress affects the neuroendocrine axis (HPA axis) and preventive and supportive measure targeted towards normalising or balancing the neurotransmitters with lifestyle management, sleep hygiene, balanced nutrition, targeted amino acid precursors and hormones, may significantly reduce the sufferings and improve the quality of life of patients suffering from chronic fatigue.


pathophysiologic basis of effects of stress and fatigue are well understood.


Declaration of interest None


January/February 2013 | prime-journal.com


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84  |  Page 85  |  Page 86  |  Page 87  |  Page 88  |  Page 89  |  Page 90  |  Page 91  |  Page 92